Cargando…

58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada

BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Piché-Renaud, Pierre-Philippe, Panetta, Luc, Farrar, Daniel, Hepburn, Charlotte Moore, Drouin, Olivier, Papenburg, Jesse, Salvadori, Marina, Laffin-Thibodeau, Melanie, Kakkar, Fatima, Morris, Shaun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586112/
http://dx.doi.org/10.1093/pch/pxac100.057
_version_ 1784813628346597376
author Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel
Hepburn, Charlotte Moore
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina
Laffin-Thibodeau, Melanie
Kakkar, Fatima
Morris, Shaun
author_facet Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel
Hepburn, Charlotte Moore
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina
Laffin-Thibodeau, Melanie
Kakkar, Fatima
Morris, Shaun
author_sort Piché-Renaud, Pierre-Philippe
collection PubMed
description BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. OBJECTIVES: The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. DESIGN/METHODS: This is a nationwide prospective observational study using the infrastructure of the Canadian Paediatric Surveillance Program. All cases of infants aged <1 year of age with microbiologically confirmed SARS-CoV-2 infection were reported from April 8th 2020 to May 31st 2021, and were classified by disease severity and primary cause of hospitalization. Multivariable logistic regression was performed to identify infants' characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions, and infants <1 month had higher odds of hospitalization than infants aged 1-3 months (Table). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSION: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having mild disease. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. [Image: see text]
format Online
Article
Text
id pubmed-9586112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95861122022-11-04 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel Hepburn, Charlotte Moore Drouin, Olivier Papenburg, Jesse Salvadori, Marina Laffin-Thibodeau, Melanie Kakkar, Fatima Morris, Shaun Paediatr Child Health Abstract / Résumés BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. OBJECTIVES: The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. DESIGN/METHODS: This is a nationwide prospective observational study using the infrastructure of the Canadian Paediatric Surveillance Program. All cases of infants aged <1 year of age with microbiologically confirmed SARS-CoV-2 infection were reported from April 8th 2020 to May 31st 2021, and were classified by disease severity and primary cause of hospitalization. Multivariable logistic regression was performed to identify infants' characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions, and infants <1 month had higher odds of hospitalization than infants aged 1-3 months (Table). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSION: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having mild disease. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. [Image: see text] Oxford University Press 2022-10-21 /pmc/articles/PMC9586112/ http://dx.doi.org/10.1093/pch/pxac100.057 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
spellingShingle Abstract / Résumés
Piché-Renaud, Pierre-Philippe
Panetta, Luc
Farrar, Daniel
Hepburn, Charlotte Moore
Drouin, Olivier
Papenburg, Jesse
Salvadori, Marina
Laffin-Thibodeau, Melanie
Kakkar, Fatima
Morris, Shaun
58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_full 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_fullStr 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_full_unstemmed 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_short 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
title_sort 58 clinical manifestations and disease severity of sars-cov-2 infection among infants in canada
topic Abstract / Résumés
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586112/
http://dx.doi.org/10.1093/pch/pxac100.057
work_keys_str_mv AT picherenaudpierrephilippe 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT panettaluc 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT farrardaniel 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT hepburncharlottemoore 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT drouinolivier 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT papenburgjesse 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT salvadorimarina 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT laffinthibodeaumelanie 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT kakkarfatima 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada
AT morrisshaun 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada